Stevens Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Stevens Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-115,086	Closed	-$2.77M	–	859
2019 Q2	$2.77M	Buy	115,086 +33,204	+41%	+$842K	0.12%	211
2019 Q1	$2.16M	Buy	+81,882	New	+$1.94M	0.09%	257
2018 Q2	–	Sell	-13,754	Closed	-$195K	–	1051
2018 Q1	$195K	Buy	+13,754	New	+$203K	0.01%	679
2017 Q2	–	Sell	-11,716	Closed	-$173K	–	1173
2017 Q1	$173K	Buy	+11,716	New	+$190K	0.01%	782
2015 Q4	–	Sell	-10,810	Closed	-$214K	–	1256
2015 Q3	$214K	Buy	+10,810	New	+$342K	0.01%	809
2015 Q2	–	Sell	-20,701	Closed	-$538K	–	1338
2015 Q1	$538K	Sell	20,701 -32,668	-61%	-$599K	0.02%	559
2014 Q4	$688K	Buy	+53,369	New	+$668K	0.02%	503
2014 Q3	–	Sell	-16,749	Closed	-$265K	–	1352
2014 Q2	$265K	Buy	+16,749	New	+$239K	0.01%	849
2014 Q1	–	Sell	-10,476	Closed	-$80K	–	1423
2013 Q4	$80K	Buy	+10,476	New	+$56.5K	﹤0.01%	974

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Stevens Capital Management's HZNP Position: Q3 2019 in Review

Stevens Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2019, closing a stake of 115,086 shares — an estimated $2.77M sold.

Stevens Capital Management first reported a position in HZNP in Q4 2013 and held it in 9 quarters. The position peaked at $2.77M in Q2 2019. 264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

Stevens Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2019 after selling out during the quarter.
Stevens Capital Management sold 115,086 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2019, an estimated $2.77M.
Stevens Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2013 and held it in 9 quarters.
Stevens Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.77M in Q2 2019.
264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on Stevens Capital Management's 13F filing for Q3 2019, filed 8 Nov 2019.